JPRN-jRCTs041220082
Recruiting
未知
Evaluation of usefulness of plasma arginine vasopressin measurement in arginine-stimulating test for diagnosis of central diabetes insipidus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Arima Hiroshi
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients below who consent to participate in this study in writing
- •1\. Patients suspected as central diabetes insipidus
- •2\. Patients already diagnosed as central diabetes insipidus
- •3\. Patients with diencephalohypophysial diseases and no symptoms of diabetes insipidus
Exclusion Criteria
- •1\. Patients with heart and renal failure
- •2\. Patients with bronchial asthma
- •Pregnant or breastfeeding patients
- •3\. Patients considered inappropriate for the participation in this study by doctors
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of plasma arginine vasopressin in hypertonic saline test in patients with diencephalohypophysial diseasesDiabetes insipidusJPRN-UMIN000020112Department of Endocrinology and Diabetes, Nagoya Graduate School of Medicine20
Active, not recruiting
Phase 1
Arginin Vasopressin im fortgeschrittenen vasodilatorischen Schock: Ein Dosisvergleich 2 vs. 4 IU/h5. Einschlusskriterien5.1. Patienten mit vasodilatorischem Schock aufgrund:a) Sepsis [Definitionen gemäss den Empfehlungen der ACCP/SCCM (12)]b) SIRS [Definitionen gemäss den Empfehlungen der ACCP/SCCM (12)]c) SIRS nach herzchirurgischen Eingriffen mit Verwendung der Herzlungen-Maschine5.2. Hypotonie (MAP <60 mmHg) trotz5.3. Noradrenalinbedarf >0,6 µg/kg/min zur Erreichung eines MAP >60 mmHgMedDRA version: 9.1Level: LLTClassification code 10021118Term: HypotoniaEUCTR2007-005010-40-ATniv.-Prof. Dr. Volker Wenzel50
Recruiting
Phase 1
Arginine effect on height growth of childreIRCT20230603058376N1Ardabil University of Medical Sciences76
Recruiting
Phase 4
To observe safety of Vasograin (a combination of Ergotamine, Paracetamol, Prochlorperazine, and Caffeine) for treating migraines in adults: an open study where all participants receive the same treatment.Health Condition 1: G430- Migraine without auraCTRI/2024/06/068686Cadila Pharmaceuticals Ltd.1,000
Active, not recruiting
Phase 1
Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR TrialAcute Kidney Injury, Liver transplantationMedDRA version: 21.0Level: LLTClassification code: 10024716Term: Liver transplantation Class: 10042613MedDRA version: 21.1Level: LLTClassification code: 10000821Term: Acute kidney failure Class: 10038359Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]CTIS2023-506512-40-00Assistance Publique Hopitaux De Paris304